Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Defends HER2 Franchise After MARIANNE Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.

You may also be interested in...



Roche’s Kadcyla Fails To Better Herceptin In First-Line Breast Cancer

Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer. Firm’s early Alzheimer’s therapy gantenerumab also fails in Phase III.

ESMO In Brief: PD-1 Updates, Perjeta’s Striking Survival, Boehringer’s Gilotrif Head-to-Head EGFR Data & More

Data for Merck’s Keytruda in bladder cancer and AstraZeneca’s CTLA-4/PD-L1 combo were among the immunotherapy updates at the 2014 ESMO meeting. Other notable releases include Perjeta’s striking survival data, a possible reprieve in lung for Endocyte’s vintafolide and head-to-head lung cancer data for Boehringer’s afatinib.

Roche’s Breast Cancer Strategy Paying Off, But Diversification Difficult

Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel